Suven Life Sciences secures Product Patent in Brazil, Eurasia

Published On 2019-03-29 04:10 GMT   |   Update On 2021-08-13 11:15 GMT

The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, said Suven Life Sciences.


Hyderabad: Suven Life Sciences Thursday said it has been granted a product patent by Brazil and Eurasia each for a new chemical entity (NCE) used in treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2023 and 2034, respectively, the company said in a BSE filing.


"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.

The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, it added.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and SUVN-911.






In addition to these clinical compounds, the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.



Also Read: Suven Life Sciences secures Product Patents in Australia and Singapore

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News